DIVISLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | DIVISLAB | Market Cap | 1,58,427 Cr. | Current Price | 5,972 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 61.6 | Book Value | 578 ₹ | Dividend Yield | 0.50 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,253 ₹ | DMA 200 | 6,233 ₹ |
| Chg in FII Hold | 0.69 % | Chg in DII Hold | -0.50 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 35.7 | MACD | -45.6 | Volume | 1,27,058 | Avg Vol 1Wk | 1,97,835 |
| Low price | 4,942 ₹ | High price | 7,078 ₹ | PEG Ratio | -6.69 | Debt to equity | 0.01 |
| 52w Index | 48.3 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 27.2 |
📊 Divi’s Laboratories (DIVISLAB) shows weak intraday potential today. RSI at 35.7 indicates oversold conditions but lacks strong reversal signals. MACD is sharply negative (-45.6), confirming bearish sentiment. Current price (5,972 ₹) is below both 50 DMA (6,253 ₹) and 200 DMA (6,233 ₹), reflecting short-term weakness. Volume (1,27,058) is below average (1,97,835), limiting breakout potential.
💡 Optimal Buy Price: 5,950–5,980 ₹ (near support)
🎯 Profit-Taking Levels: 6,050–6,100 ₹ (short-term resistance)
🛑 Stop-Loss: 5,920 ₹ (recent low)
⏳ If already holding intraday: Exit near 6,050–6,070 ₹ if momentum weakens or if price fails to sustain above 5,980 ₹ with volume confirmation.
Positive
- Strong ROCE (20.6%) and ROE (15.6%) indicate efficient capital use.
- Debt-to-equity ratio of 0.01 reflects near debt-free status.
- EPS of 94.8 ₹ supports earnings strength.
- FII holdings increased (+0.69%), showing foreign investor confidence.
- 52-week performance is strong (+48.3%).
Limitation
- Stock trading below both 50 DMA and 200 DMA indicates bearish trend.
- Quarterly PAT declined from 696 Cr. to 653 Cr.
- DII holdings decreased (-0.50%), reflecting reduced domestic institutional support.
- High P/E (61.6) compared to industry average (27.2), suggesting overvaluation.
- Volume below average, limiting intraday opportunities.
Company Negative News
- No major negative news reported, but weak technicals and declining quarterly profits weigh on sentiment.
Company Positive News
- EPS of 94.8 ₹ and strong ROCE/ROE highlight solid fundamentals.
- FII inflows indicate foreign confidence in the company.
Industry
- Industry P/E at 27.2 is much lower than Divi’s Laboratories’ 61.6, suggesting relative overvaluation.
- Pharmaceutical sector remains resilient, supported by global demand but faces pricing and regulatory pressures.
Conclusion
⚠️ Divi’s Laboratories is not an ideal intraday candidate today due to weak momentum, declining profits, and price trading below key averages. Short-term traders may attempt a bounce trade near 5,950–5,980 ₹ with a tight stop-loss at 5,920 ₹, but risk remains elevated. Conservative traders should avoid aggressive intraday positions until momentum indicators improve.